About
44
Publications
1,690
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
260
Citations
Introduction
Skills and Expertise
Publications
Publications (44)
Brain metastases (BM) represent a growing problem for breast cancer (BC) patients. Recent studies have demonstrated a strong impact of the BC molecular subtype on the incidence of BM development. This study explores the interaction between BC cells of different molecular subtypes and the blood-brain barrier (BBB). We compared the ability of BC cell...
Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC...
Purpose Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of patients with these two therapy options. Therefore, i...
[This corrects the article DOI: 10.1055/a-1286-2917.].
Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to sympt...
Purpose
Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i+ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR+HER2–) breast cancer (BC). However, real-world data on the implementation of therapy usage, efficacy, and toxicity have not yet been reported.
Methods
The PRAEGNANT registry was used to i...
Background:
The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS metastases as a first site of metastatic disease in breast cancer patients. Moreover, the incidence of CNS metastases afte...
This meta-analysis and systematic review investigated evidence of the effect of oral micronutrient supplementation on male fertility. Following searches of PubMed, Ovid/Ovid Medline(r) and Embase, 18 randomized, double-blind, placebo-controlled trials were included in the meta-analysis (seven studies) and/or the systematic review (12 studies). The...
Background
The incidence of brain metastases from breast cancer is increasing and treatment is a major challenge. Different scores were developed to estimate the prognosis of patients with brain metastases by objective criteria. Sperduto et al. established the disease-specific breast-graded prognostic assessment (GPA) score in 400 breast cancer pat...
The incidence of breast cancer brain metastases has risen steadily in recent years. Brain metastases are often the limiting factor of the disease, as survival is usually only a few months after brain metastasis occurs. Apart from the poor prognosis, cognitive and neurological deficits lead to a massive impairment of quality of life. HER2-positive o...
Background:
Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.
Methods:
We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.
Results:...
Background: The incidence of brain metastases (BM) in breast cancer patients is rising and has become a major clinical challenge. So far, the incidence of BM after modern neoadjuvant treatment is not clear.
Materials and Methods: In Geparquinto, patients with untreated HER2-positive breast cancer (n=615) received either lapatinib or trastuzumab, pa...
Background:
The incidence of brain metastases (BM) in breast cancer patients has increased. Many retrospective analyses have shown that first-line treatment with trastuzumab prolongs survival in patients with HER2-positive BM. In contrast, the evidence for other therapies targeting HER2 for patients with BM is rare.
Methods:
The aim of this revi...
Background
Although some studies suggest that breast-conserving therapy (BCT) shows better psychosocial outcomes than mastectomy in patients with primary breast cancer, little is known about the outcomes of these surgical options in recurrent breast cancer. We investigated differences in overall survival and re-recurrence rates as well as psychosoc...
Background:
Breast cancer is one of the most frequent causes of leptomeningeal metastasis (LM) among solid tumors in adults. The prognosis of patients with LM is poor. A treatment option is the intrathecal administration of liposomal cytarabine.
Case reports:
The first case represents a 53-year-old woman with LM of breast cancer. A neurological...
Background
The incidence of brain metastases in breast cancer patients has increased in the last years. However, the knowledge about tumor cell invasion in the brain is still very limited. Based on our recent study on cDNA microarray data of breast cancer patients, we hypothesized that two enzymes involved in the hyaluronan metabolism, namely, hyal...
Evidence about distribution patterns of brain metastases with regard to breast cancer subtypes and its influence on the prognosis of patients is insufficient. Clinical data, cranial computed tomography (CT) and magnetic resonance imaging (MRI) scans of 300 breast cancer patients with brain metastases (BMs) were collected retrospectively in four cen...
Bei einem intramammaren Rezidiv eines Mammakarzinoms wird meist eine Mastektomie empfohlen, in begrundeten Fallen kann auch ein zweites brusterhaltendes Vorgehen erwogen werden. Der Zusammenhang zwischen Lebensqualitat bei Patientinnen mit der Erstdiagnose eines Mammakarzinoms und Art der operativen Therapie ist vielfach untersucht worden. Zur Lebe...
Zielsetzung: Die Inzidenz der Hirnmetastasierung beim Mammakarzinom steigt in den letzten Jahren. Es ist bislang unklar, ob sich die Lokalisation der Metastasen bei verschiedenen biologischen Subtypen und unter verschiedenen Therapieansatzen unterscheiden. Ziel dieser Arbeit war es, das Hirnmetastasierungsmuster bei Mammakarzinom-Patientinnen zu an...
Zielsetzung: Die Inzidenz der Hirnmetastasierung bei Mammakarzinom-Patienten steigt in den letzten Jahren. Es gibt jedoch nur wenige evidenzbasierte therapeutische Ansatze bei cerebralen Metastasen eines Mammakarzinoms. Die Datenlage zu den tumorbiologischen Grundlagen cerebraler Metastasierung ist ebenfalls unzureichend. In dem Projekt Brain Metas...
Purpose:
Several prognostic indices (PI) have been developed to stratify patients with brain metastases in groups with good or bad prognosis. The aim of our study was to compare nine prognostic scores for patients with brain metastases (BM) of breast cancer receiving radiotherapy.
Methods:
The clinical data of 139 breast cancer patients with BM...
Einleitung/Zielsetzung: Die Inzidenz von Hirnmetastasen beim Mammakarzinom ist in den letzten Jahren gestiegen. Immer noch stellen Hirnmetastasen einen limitierenden Faktor fur das Uberleben dar. Es gibt eine Vielzahl von moglichen Therapien, aber die Selektion der Patientinnen fur die entsprechende Therapiemodalitat bleibt uneinheitlich und wird k...
Background: The incidence of brain metastases in breast cancer patients is rising and has become a major clinical challenge in the last years. So far, limited therapeutic options and insights into the biology of brain metastases exist. Most reports include patients with brain metastases from different tumor entities and few studies so far analyzed...
Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX
Background: The incidence of brain metastases in breast cancer patients is rising and has become a major clinical challenge in the last years with so far limited therapeutic options. Therefore, further insights into the biology of brain tropis...
Protein levels of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) determined by enzyme-linked immunosorbent assay from fresh-frozen tumor tissue have been evaluated as prognostic factors in prospectively randomized trials in breast cancer. However, the role of uPA and PAI-1 in the context of breast cancer subtypes and for mRNA expre...
Distribution of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression in all three cohorts.
Overall survival in the untreated group of patients (cohort B) according to PAI-1 protein levels (A) and uPA protein levels (B).
Abbreviations: ELISA, enzyme-linked immunosorbent assay; uPA, urokinase plasminogen activator; PAI-1, plasminogen activator inhibitor.
Zielsetzung: Bei Patientinnen mit einem Mammakarzinom ist eine zunehmende Inzidenz zerebraler Metastasierung zu beobachten. Es fehlen klinische evidenzbasierte Daten zu den Behandlungsmoglichkeiten sowie experimentelle Untersuchungen zu Entstehungsmechanismen. Deshalb wird die Registerstudie „Brain Metastases in Breast Cancer Network Germany“ (BMBC...
The systematic review examines whether Cimicifuga racemosa (CR), Hypericum perforatum (HP), Agnus castus, vitamins and minerals, either as monotherapy or in combination, have an evidence-based impact on vasomotor, genital and psychological climacteric complaints. DATA SOURCES AND METHODS OF STUDY SELECTION: We searched in the databases EMBASE, OVID...
